Publication: 2448

Publication: 2448

A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

URL

URL

Google Scholar

Citation:: Cancer Res vol 76 (14 suppl) abstr 2037

Meeting Instance:: AACR 2016
Year:: 2016
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3894

Program:: TRP
Primary Committee:: PPP
Sec. Committees:

Pharmas:: Genentech
Grants:: U10CA180821

Corr. Author:
Authors:: Jai N. Patel Chen Jiang Kouros Owzar Daniel L. Hertz Flora A. Mulkey William K. Kelly Susan Halabi Yoichi Furukawa Cameron Lassiter Susan G. Dorsey Paula N. Friedman Eric J. Small Phillip G. Febbo Deanna L. Kroetz Michael A. Carducci John F. Mahoney Michael J. Kelley Yusuke Nakamura Michiaki Kubo Mark J. Ratain Michael J. Morris Howard L. McLeod

Networks:: CA824, LAPS-IL036, LAPS-IL057, LAPS-MD017, LAPS-MN026, LAPS-NC007, LAPS-NY016, NC002

Study: CALGB-90401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: